Business
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer Strong presence at ASH includes
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer\nStrong presence at ASH includes 11 presentations spanning Jazz's portfolio, advancing research into difficult-to-treat blood cancers and diseases\nReal-world data at NACLC reinforce clinical impact of Zepzelca® (lurbinectedin) in small cell lung cancer\nDUBLIN, Nov. 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9; 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12; and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3. New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).\n\"Following recent trial results showing the potential of zanidatamab to treat HER2-expressing gastric and biliary tract cancers at ASCO GI, ASCO and ESMO this year, we're excited to share updated data at SABCS in HER2-amplified and hormone receptor-positive metastatic breast cancer when zanidatamab is used in combination to target the HER2, CDK4/6 and hormone receptor pathways,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. \"SABCS will also feature data from a trial of zanidatamab in neoadjuvant breast cancer. Additionally, we look forward to sharing new data through numerous presentations at ASH 2023 that underscore our commitment to improving standards of care in blood cancer and other hematologic diseases, as well as real-world findings at NACLC that provide evidence of Zepzelca's safety in clinical practice for the treatment of second-line small cell lung cancer.\"\nNotable presentations at this year's SABCS, ASH and NACLC meetings include:\nA SABCS oral presentation (late-breaking abstract) featuring primary results from a Phase 2a study for a chemotherapy-free option in heavily pretreated patients with HER2+/HR+ mBC treated with the combi...